Born in Mumbai, Reshma moved to the United States in 1988. She pursued a career in medicine, earning her degree from Boston ...

Trained in internal medicine and nephrology, Reshma once intended to teach, treat patients, and work in a lab after medical ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Reshma is the kind of leader who can deliver that extraordinary future—it only seems crazy because no one’s done it before. I ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and ...

Designed to provide broad exposure to the Large Cap Growth segment of the US equity market, the First Trust NASDAQ-100 Ex-Technology Sector ETF (QQXT) is a passively managed exchange traded fund ...

NRI PULSE STAFF REPORT Indian American physician-scientist and business executive Reshma Kewalramani, the CEO of Vertex ...

Representative Jefferson Shreve recently dipped into Vertex Pharmaceuticals stock, buying between $15,001 and $50,000 worth on March 13th. He revealed this transaction in a disclosure dated April 11th ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug ...